Rectify is developing Positive Functional Modulators (PFMs) that restore the function of ABC transporters as disease‑modifying therapies for patients with serious genetic diseases. Its pipeline targets loss‑of‑function mutations across multiple organ systems, including the lungs, liver, gastrointestinal tract, eye, and central nervous system. The company was founded by Jonathan Moore with Atlas Venture in 2020, was seeded and launched by Atlas Venture, and is headquartered in Cambridge, Massachusetts. Leadership includes President and CEO Rajesh Devraj and Founder/CSO Jonathan Moore, supported by a board and scientific advisory group with drug‑discovery and structural biology expertise. Rectify plans to use its new financing to fund the company through its first human proof‑of‑concept studies. The company positions PFMs as a platform approach to expand the application of transporter‑restoring precision therapies beyond CFTR to other ABC transporter‑linked diseases.

Total raised

$100M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2021